CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Innovus Pharmaceuticals, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Innovus Pharmaceuticals, Inc.
8845 Rehco Road
Phone: (858) 964-5123p:858 964-5123 San Diego, CA  92121-3261  United States Fax: (858) 964-2301f:858 964-2301
This company was Merged or Acquired on 2/14/2020.
This company ceased filing statements with the SEC on 2/26/2020.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Innovus Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases. The Company markets approximately 28 products in the United States and with 12 of those being marketed and sold in multiple countries around the world through some of our 18 international commercial partners. Its products include Vesele, Zestra, Zestra Glide, EjectDelay, Sensum+, Beyond Human, RecalMax, Beyond Human Omega 3 Fish Oil, Beyond Human Eagle Vision Formula, Beyond Human Blood Sugar, Beyond Human Colon Cleanse, Beyond Human Green Coffee ,Beyond Human Growth Agent, RecalMax for brain health, Androferti, UriVarx, PEVarx, ProstaGorx, FlutiCare, Apeaz, AllerVarx, ArthriVarx, Xyralid, Can-C Eye Drops, Can-C capsules, MZS, and Diabasens.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/201912/31/2018YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
6770 Blank checks
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Director Bassam B.Damaj 50 4/27/2018 1/22/2013
Chief Financial Officer, Vice President RyanSelhorn 37 4/27/2018 4/27/2018
Executive Vice President, Corporate Development, and General Counsel, Secretary Randy J.Berholtz 57 1/9/2017 1/9/2017
3 additional Officers and Directors records available in full report.

Business Names
Business Name
Beyond Human, LLC
FasTrack Pharmaceuticals, Inc.
INNV
6 additional Business Names available in full report.

General Information
Number of Employees: 1 (As of 12/31/2012)
Outstanding Shares: 3,204,401 (As of 1/15/2020)
Shareholders: 503
Stock Exchange: OTC
Federal Tax Id: 870324697
Fax Number: (858) 964-2301


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023